| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 20 | 2023 | 277 | 2.840 |
Why?
|
| Puerto Rico | 38 | 2024 | 1378 | 2.200 |
Why?
|
| Neoplasms | 17 | 2023 | 1103 | 2.130 |
Why?
|
| Papillomavirus Infections | 18 | 2022 | 336 | 2.040 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2022 | 30 | 1.060 |
Why?
|
| Papillomaviridae | 8 | 2015 | 127 | 0.960 |
Why?
|
| Early Detection of Cancer | 7 | 2023 | 336 | 0.940 |
Why?
|
| Terminal Care | 2 | 2021 | 45 | 0.940 |
Why?
|
| Papillomavirus Vaccines | 3 | 2022 | 151 | 0.930 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 15 | 0.870 |
Why?
|
| Registries | 5 | 2019 | 335 | 0.810 |
Why?
|
| Hospice Care | 1 | 2021 | 15 | 0.780 |
Why?
|
| Humans | 77 | 2024 | 37093 | 0.770 |
Why?
|
| Female | 63 | 2024 | 20969 | 0.760 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 88 | 0.720 |
Why?
|
| United States | 17 | 2024 | 4223 | 0.710 |
Why?
|
| Vaginal Smears | 7 | 2013 | 57 | 0.700 |
Why?
|
| Breast Neoplasms | 9 | 2022 | 1502 | 0.670 |
Why?
|
| Aged | 30 | 2024 | 6741 | 0.670 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 37 | 0.660 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 358 | 0.630 |
Why?
|
| Adult | 42 | 2023 | 11712 | 0.610 |
Why?
|
| Middle Aged | 40 | 2024 | 10129 | 0.570 |
Why?
|
| Patient Acceptance of Health Care | 7 | 2023 | 404 | 0.520 |
Why?
|
| Health Knowledge, Attitudes, Practice | 7 | 2022 | 864 | 0.500 |
Why?
|
| Sunscreening Agents | 1 | 2014 | 9 | 0.490 |
Why?
|
| Young Adult | 17 | 2021 | 4268 | 0.490 |
Why?
|
| Adolescent | 19 | 2021 | 5363 | 0.480 |
Why?
|
| Sunlight | 1 | 2014 | 47 | 0.480 |
Why?
|
| Risk Factors | 12 | 2022 | 3562 | 0.480 |
Why?
|
| Retrospective Studies | 11 | 2022 | 2026 | 0.460 |
Why?
|
| Self Administration | 1 | 2013 | 42 | 0.440 |
Why?
|
| Multiple Myeloma | 2 | 2024 | 39 | 0.440 |
Why?
|
| Health Behavior | 3 | 2023 | 537 | 0.440 |
Why?
|
| Specimen Handling | 1 | 2013 | 56 | 0.440 |
Why?
|
| SEER Program | 5 | 2024 | 91 | 0.420 |
Why?
|
| Incidence | 11 | 2024 | 922 | 0.420 |
Why?
|
| Ambulatory Care | 1 | 2013 | 75 | 0.420 |
Why?
|
| Environmental Exposure | 1 | 2014 | 216 | 0.420 |
Why?
|
| Medicare | 3 | 2022 | 195 | 0.410 |
Why?
|
| Genetic Testing | 1 | 2011 | 75 | 0.380 |
Why?
|
| Palliative Care | 2 | 2021 | 49 | 0.360 |
Why?
|
| Information Seeking Behavior | 1 | 2010 | 26 | 0.340 |
Why?
|
| Uterine Cervical Dysplasia | 5 | 2007 | 39 | 0.330 |
Why?
|
| Health Personnel | 2 | 2022 | 228 | 0.330 |
Why?
|
| DNA, Viral | 6 | 2015 | 304 | 0.320 |
Why?
|
| Attitude to Health | 2 | 2011 | 325 | 0.310 |
Why?
|
| Colorectal Neoplasms | 2 | 2023 | 441 | 0.300 |
Why?
|
| Health Services Accessibility | 6 | 2021 | 560 | 0.290 |
Why?
|
| Language | 2 | 2021 | 157 | 0.290 |
Why?
|
| Endometrial Neoplasms | 4 | 2011 | 66 | 0.290 |
Why?
|
| Cancer Care Facilities | 2 | 2010 | 17 | 0.280 |
Why?
|
| Health Status Disparities | 3 | 2019 | 642 | 0.270 |
Why?
|
| Communication Barriers | 1 | 2006 | 56 | 0.270 |
Why?
|
| Male | 20 | 2024 | 20025 | 0.270 |
Why?
|
| Decision Making | 2 | 2006 | 203 | 0.250 |
Why?
|
| Aged, 80 and over | 10 | 2019 | 2379 | 0.240 |
Why?
|
| Patient Education as Topic | 2 | 2019 | 215 | 0.240 |
Why?
|
| Mass Screening | 4 | 2012 | 462 | 0.240 |
Why?
|
| Texas | 9 | 2010 | 324 | 0.230 |
Why?
|
| Benzodiazepines | 1 | 2023 | 15 | 0.230 |
Why?
|
| Socioeconomic Factors | 4 | 2006 | 1067 | 0.230 |
Why?
|
| Caribbean Region | 5 | 2023 | 69 | 0.230 |
Why?
|
| Hospital Mortality | 1 | 2005 | 187 | 0.230 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2023 | 4 | 0.220 |
Why?
|
| Occult Blood | 1 | 2023 | 29 | 0.220 |
Why?
|
| Paraproteinemias | 1 | 2023 | 4 | 0.220 |
Why?
|
| Cytogenetics | 1 | 2022 | 3 | 0.220 |
Why?
|
| Civil Defense | 1 | 2023 | 11 | 0.220 |
Why?
|
| Cervix Uteri | 2 | 2013 | 42 | 0.210 |
Why?
|
| Prognosis | 3 | 2022 | 739 | 0.210 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2022 | 41 | 0.210 |
Why?
|
| Sexual Behavior | 4 | 2011 | 609 | 0.210 |
Why?
|
| Genetic Markers | 1 | 2022 | 142 | 0.210 |
Why?
|
| Sex Factors | 4 | 2014 | 898 | 0.210 |
Why?
|
| Quality of Life | 3 | 2021 | 481 | 0.200 |
Why?
|
| Cyclonic Storms | 1 | 2023 | 64 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 1 | 2022 | 191 | 0.200 |
Why?
|
| Agriculture | 3 | 2005 | 56 | 0.190 |
Why?
|
| Recombinant Proteins | 1 | 2022 | 515 | 0.190 |
Why?
|
| Population Surveillance | 2 | 2019 | 238 | 0.190 |
Why?
|
| Vaccination | 1 | 2022 | 288 | 0.190 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 182 | 0.190 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 494 | 0.190 |
Why?
|
| Prevalence | 3 | 2018 | 1455 | 0.170 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 208 | 0.170 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 159 | 0.170 |
Why?
|
| Uterine Neoplasms | 1 | 2019 | 39 | 0.170 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 97 | 0.170 |
Why?
|
| Social Class | 5 | 2011 | 247 | 0.170 |
Why?
|
| Capacity Building | 1 | 2019 | 87 | 0.170 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 37 | 0.160 |
Why?
|
| Mammography | 4 | 2009 | 188 | 0.150 |
Why?
|
| Survival Rate | 5 | 2021 | 311 | 0.150 |
Why?
|
| Health Services Misuse | 1 | 2017 | 12 | 0.150 |
Why?
|
| Case-Control Studies | 9 | 2006 | 1130 | 0.150 |
Why?
|
| Oncogene Proteins, Viral | 3 | 2005 | 25 | 0.150 |
Why?
|
| Logistic Models | 7 | 2015 | 923 | 0.140 |
Why?
|
| Age Factors | 4 | 2014 | 1033 | 0.140 |
Why?
|
| Insulin Resistance | 2 | 2011 | 184 | 0.140 |
Why?
|
| Poverty | 2 | 2009 | 348 | 0.130 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 186 | 0.130 |
Why?
|
| Uterine Cervical Diseases | 2 | 2013 | 14 | 0.130 |
Why?
|
| Public Health | 1 | 2019 | 372 | 0.130 |
Why?
|
| Mexican Americans | 2 | 2009 | 189 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2005 | 128 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2019 | 400 | 0.130 |
Why?
|
| Protective Clothing | 1 | 2014 | 6 | 0.120 |
Why?
|
| Repressor Proteins | 3 | 2005 | 249 | 0.120 |
Why?
|
| Ovarian Neoplasms | 3 | 2002 | 312 | 0.120 |
Why?
|
| Multivariate Analysis | 4 | 2015 | 583 | 0.120 |
Why?
|
| Unsafe Sex | 2 | 2012 | 161 | 0.120 |
Why?
|
| Anus Diseases | 1 | 2013 | 17 | 0.110 |
Why?
|
| Anal Canal | 1 | 2012 | 30 | 0.110 |
Why?
|
| Health Surveys | 1 | 2014 | 373 | 0.110 |
Why?
|
| Cultural Characteristics | 3 | 2011 | 125 | 0.110 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 215 | 0.100 |
Why?
|
| Latin America | 2 | 2023 | 45 | 0.100 |
Why?
|
| Survival Analysis | 3 | 2014 | 325 | 0.100 |
Why?
|
| Biotechnology | 1 | 2011 | 15 | 0.100 |
Why?
|
| Insurance, Health | 3 | 2022 | 126 | 0.100 |
Why?
|
| Consumer Health Information | 1 | 2011 | 22 | 0.100 |
Why?
|
| Marketing | 1 | 2011 | 40 | 0.100 |
Why?
|
| User-Computer Interface | 1 | 2011 | 62 | 0.100 |
Why?
|
| Self Care | 1 | 2012 | 159 | 0.100 |
Why?
|
| Neoplasm Staging | 5 | 2018 | 275 | 0.100 |
Why?
|
| Health Promotion | 2 | 2009 | 653 | 0.100 |
Why?
|
| Comprehensive Health Care | 1 | 2010 | 10 | 0.090 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2010 | 9 | 0.090 |
Why?
|
| Genotype | 1 | 2013 | 730 | 0.090 |
Why?
|
| Self Efficacy | 2 | 2009 | 184 | 0.090 |
Why?
|
| Evidence-Based Practice | 1 | 2010 | 45 | 0.090 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 197 | 0.090 |
Why?
|
| Human papillomavirus 16 | 2 | 2007 | 35 | 0.080 |
Why?
|
| Genital Neoplasms, Male | 1 | 2008 | 2 | 0.080 |
Why?
|
| Genital Diseases, Male | 1 | 2008 | 2 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2010 | 178 | 0.080 |
Why?
|
| Women's Health | 2 | 2006 | 145 | 0.080 |
Why?
|
| Condylomata Acuminata | 1 | 2008 | 6 | 0.080 |
Why?
|
| Trust | 1 | 2010 | 133 | 0.080 |
Why?
|
| Educational Status | 1 | 2010 | 313 | 0.080 |
Why?
|
| Internet | 1 | 2010 | 211 | 0.080 |
Why?
|
| Health Education | 1 | 2011 | 338 | 0.080 |
Why?
|
| Ploidies | 1 | 2007 | 5 | 0.080 |
Why?
|
| Program Development | 1 | 2009 | 233 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2004 | 23 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2007 | 1207 | 0.070 |
Why?
|
| Qualitative Research | 1 | 2010 | 446 | 0.070 |
Why?
|
| Chromosome Aberrations | 1 | 2007 | 60 | 0.070 |
Why?
|
| Carcinoma | 1 | 2007 | 96 | 0.070 |
Why?
|
| Cross-Sectional Studies | 5 | 2015 | 2721 | 0.070 |
Why?
|
| Chromatin | 1 | 2007 | 169 | 0.070 |
Why?
|
| Adiponectin | 1 | 2006 | 55 | 0.070 |
Why?
|
| Patient Participation | 1 | 2006 | 75 | 0.070 |
Why?
|
| Patient Satisfaction | 1 | 2006 | 145 | 0.070 |
Why?
|
| Physician-Patient Relations | 1 | 2006 | 128 | 0.060 |
Why?
|
| Survivors | 1 | 2006 | 136 | 0.060 |
Why?
|
| Air Pollutants, Occupational | 1 | 2005 | 9 | 0.060 |
Why?
|
| Wood | 1 | 2005 | 16 | 0.060 |
Why?
|
| Transients and Migrants | 1 | 2005 | 39 | 0.060 |
Why?
|
| DNA-Binding Proteins | 2 | 2005 | 539 | 0.060 |
Why?
|
| Women | 1 | 2005 | 27 | 0.060 |
Why?
|
| Dust | 1 | 2005 | 54 | 0.060 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2004 | 23 | 0.060 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2004 | 7 | 0.060 |
Why?
|
| Quality of Health Care | 1 | 2005 | 138 | 0.060 |
Why?
|
| Vulvar Neoplasms | 1 | 2004 | 12 | 0.060 |
Why?
|
| Odds Ratio | 4 | 2010 | 534 | 0.060 |
Why?
|
| Acculturation | 1 | 2005 | 188 | 0.060 |
Why?
|
| Risk Assessment | 4 | 2010 | 753 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2004 | 67 | 0.060 |
Why?
|
| Pilot Projects | 3 | 2012 | 661 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2005 | 550 | 0.060 |
Why?
|
| Antibodies, Viral | 1 | 2005 | 262 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2005 | 308 | 0.060 |
Why?
|
| Guam | 1 | 2023 | 79 | 0.060 |
Why?
|
| Efficiency | 1 | 2003 | 16 | 0.060 |
Why?
|
| Research Design | 1 | 2005 | 313 | 0.060 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2003 | 70 | 0.060 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2023 | 56 | 0.050 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2002 | 3 | 0.050 |
Why?
|
| Gynecology | 1 | 2003 | 31 | 0.050 |
Why?
|
| Peritoneal Neoplasms | 1 | 2002 | 16 | 0.050 |
Why?
|
| Menopause | 1 | 2003 | 56 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 2003 | 82 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2003 | 55 | 0.050 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2002 | 35 | 0.050 |
Why?
|
| Adenofibroma | 1 | 2002 | 1 | 0.050 |
Why?
|
| Thyroid Diseases | 1 | 2002 | 4 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2018 | 113 | 0.050 |
Why?
|
| Confidence Intervals | 3 | 2010 | 149 | 0.050 |
Why?
|
| Mentors | 1 | 2003 | 127 | 0.050 |
Why?
|
| Endometriosis | 1 | 2002 | 73 | 0.050 |
Why?
|
| Emotions | 1 | 2023 | 220 | 0.050 |
Why?
|
| Disease Progression | 1 | 2023 | 601 | 0.050 |
Why?
|
| Data Collection | 2 | 2015 | 194 | 0.040 |
Why?
|
| Pamphlets | 1 | 2019 | 26 | 0.040 |
Why?
|
| International Cooperation | 1 | 2019 | 46 | 0.040 |
Why?
|
| Medical Tourism | 1 | 2019 | 4 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 484 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2006 | 448 | 0.040 |
Why?
|
| International Agencies | 1 | 2019 | 6 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2019 | 30 | 0.040 |
Why?
|
| Sex Distribution | 2 | 2010 | 215 | 0.040 |
Why?
|
| Developing Countries | 1 | 2019 | 99 | 0.040 |
Why?
|
| Cause of Death | 1 | 2019 | 156 | 0.040 |
Why?
|
| Tumor Virus Infections | 2 | 2010 | 26 | 0.040 |
Why?
|
| Hospitalization | 1 | 2021 | 388 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 16 | 0.040 |
Why?
|
| Mastectomy, Segmental | 1 | 2017 | 17 | 0.040 |
Why?
|
| Age Distribution | 2 | 2010 | 225 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 276 | 0.030 |
Why?
|
| Diet | 1 | 2003 | 801 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 291 | 0.030 |
Why?
|
| Interviews as Topic | 2 | 2009 | 381 | 0.030 |
Why?
|
| Pregnancy | 2 | 2011 | 1549 | 0.030 |
Why?
|
| California | 2 | 2009 | 476 | 0.030 |
Why?
|
| Papillomavirus E7 Proteins | 2 | 2005 | 11 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2007 | 400 | 0.030 |
Why?
|
| Insurance Coverage | 2 | 2005 | 100 | 0.030 |
Why?
|
| Aging | 1 | 2019 | 664 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 208 | 0.030 |
Why?
|
| Body Mass Index | 2 | 2011 | 854 | 0.030 |
Why?
|
| Sentinel Surveillance | 1 | 2014 | 21 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2015 | 242 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2014 | 76 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2010 | 1492 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2006 | 441 | 0.030 |
Why?
|
| Mexico | 2 | 2005 | 240 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2012 | 61 | 0.030 |
Why?
|
| Risk-Taking | 1 | 2015 | 451 | 0.030 |
Why?
|
| Child | 2 | 2011 | 3131 | 0.030 |
Why?
|
| Comorbidity | 1 | 2014 | 623 | 0.030 |
Why?
|
| Coitus | 1 | 2011 | 13 | 0.020 |
Why?
|
| Multimedia | 1 | 2011 | 17 | 0.020 |
Why?
|
| Pregnancy in Adolescence | 1 | 2011 | 32 | 0.020 |
Why?
|
| Parity | 1 | 2011 | 46 | 0.020 |
Why?
|
| Oklahoma | 1 | 2010 | 29 | 0.020 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2010 | 14 | 0.020 |
Why?
|
| Alaska | 1 | 2010 | 53 | 0.020 |
Why?
|
| Community Health Planning | 1 | 2010 | 35 | 0.020 |
Why?
|
| Micronesia | 1 | 2010 | 80 | 0.020 |
Why?
|
| Medical History Taking | 1 | 2010 | 33 | 0.020 |
Why?
|
| Population Groups | 1 | 2010 | 56 | 0.020 |
Why?
|
| Reference Values | 1 | 2010 | 212 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 339 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 455 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2010 | 78 | 0.020 |
Why?
|
| Schools | 1 | 2011 | 260 | 0.020 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2011 | 164 | 0.020 |
Why?
|
| Curriculum | 1 | 2011 | 265 | 0.020 |
Why?
|
| Respiratory Tract Infections | 1 | 2008 | 33 | 0.020 |
Why?
|
| Indians, North American | 1 | 2010 | 159 | 0.020 |
Why?
|
| Sexual Partners | 1 | 2011 | 314 | 0.020 |
Why?
|
| Human papillomavirus 18 | 1 | 2007 | 5 | 0.020 |
Why?
|
| Image Cytometry | 1 | 2007 | 7 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2009 | 180 | 0.020 |
Why?
|
| Anus Neoplasms | 1 | 2008 | 49 | 0.020 |
Why?
|
| Virus Integration | 1 | 2007 | 58 | 0.020 |
Why?
|
| Biopsy | 1 | 2007 | 164 | 0.020 |
Why?
|
| Psychometrics | 1 | 2009 | 318 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2011 | 1378 | 0.020 |
Why?
|
| Outpatients | 1 | 2006 | 33 | 0.020 |
Why?
|
| Hela Cells | 1 | 2007 | 366 | 0.020 |
Why?
|
| Medically Uninsured | 1 | 2006 | 56 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 448 | 0.020 |
Why?
|
| Time Factors | 1 | 2010 | 1742 | 0.020 |
Why?
|
| New Mexico | 1 | 2005 | 31 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 623 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2007 | 301 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2006 | 77 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2005 | 34 | 0.020 |
Why?
|
| Infant | 1 | 2009 | 1046 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 2005 | 58 | 0.020 |
Why?
|
| Endometrium | 1 | 2006 | 60 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2005 | 9 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 485 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2005 | 70 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2005 | 54 | 0.020 |
Why?
|
| Breast Self-Examination | 1 | 2005 | 12 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2005 | 59 | 0.020 |
Why?
|
| Physical Examination | 1 | 2005 | 43 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2005 | 136 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2009 | 1418 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2006 | 212 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 237 | 0.020 |
Why?
|
| Rosaniline Dyes | 1 | 2004 | 2 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2004 | 22 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 191 | 0.010 |
Why?
|
| Contraceptives, Oral | 1 | 2003 | 14 | 0.010 |
Why?
|
| Social Support | 1 | 2006 | 394 | 0.010 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2003 | 9 | 0.010 |
Why?
|
| Rural Population | 1 | 2005 | 294 | 0.010 |
Why?
|
| Fellowships and Scholarships | 1 | 2003 | 29 | 0.010 |
Why?
|
| Dietary Fiber | 1 | 2003 | 47 | 0.010 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2002 | 15 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 997 | 0.010 |
Why?
|
| Risk | 1 | 2003 | 267 | 0.010 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2002 | 18 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2003 | 337 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 1180 | 0.010 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2002 | 14 | 0.010 |
Why?
|
| Obesity | 1 | 2011 | 1067 | 0.010 |
Why?
|
| Carotenoids | 1 | 2003 | 70 | 0.010 |
Why?
|
| Diet Surveys | 1 | 2003 | 101 | 0.010 |
Why?
|
| Vitamin E | 1 | 2003 | 61 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 562 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 1568 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2002 | 148 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2003 | 617 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2003 | 213 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2002 | 974 | 0.010 |
Why?
|
| Hypertension | 1 | 2006 | 796 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2003 | 454 | 0.010 |
Why?
|
| Smoking | 1 | 2005 | 940 | 0.010 |
Why?
|
| HIV Infections | 1 | 2011 | 2303 | 0.010 |
Why?
|
| Mice | 1 | 2003 | 5913 | 0.010 |
Why?
|
| Animals | 1 | 2003 | 15081 | 0.000 |
Why?
|